Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Integration
We set out the parameters a method disclosure would contain, all of which are known to whoever ran the sample and none of which is commercially sensitive.
A reversed-phase separation is an equilibrium argument. The stationary phase is a hydrophobic ligand bonded to a porous silica or polymer particle; the mobile phase is water with an organic modifier, usually acetonitrile, and an acidic additive. A peptide partitions between the two according to its hydrophobicity, and as the organic fraction rises over the course of a programmed gradient, species elute in approximate order of that hydrophobicity. Everything that follows — resolution, peak shape, the visibility of a small impurity beside a large parent — is a consequence of how that partitioning has been arranged.
A pump delivers a mixture of two solvents in a proportion that changes over time under program control. An autosampler injects a measured volume of dissolved sample into that stream. The stream passes through a column packed with particles bearing a bonded hydrophobic ligand, held in a thermostatted compartment. Analytes partition between the mobile phase and the stationary phase; as the organic fraction of the mobile phase rises, each species reaches a composition at which it prefers the mobile phase and leaves the column. A detector at the outlet measures ultraviolet absorbance continuously. Software records the signal and integrates it.
Peptides behave unusually within that framework, in a way worth knowing. Their retention is extremely sensitive to organic composition — much more so than small molecules — which means peptides do not so much elute gradually as leave the column over a narrow composition window. This is why isocratic separation of peptides is impractical and why gradient slope dominates the outcome. It is also why small changes to a gradient programme produce disproportionate changes in resolution.
Every element in the chain is a variable that a method disclosure would specify: column dimensions, particle and pore size, bonded phase, temperature, mobile-phase composition and additive, flow rate, gradient programme, injection volume and sample concentration, detection wavelength and bandwidth. Twelve numbers, all known to the analyst.1
Column choice sets the ceiling on what any gradient can achieve. Three parameters dominate. Particle size governs efficiency: reducing it narrows peaks, and the shift from five-micron to sub-two-micron packings over the past two decades is the reason a modern separation can resolve in ten minutes what once took forty, at the cost of much higher operating pressure and instruments built for it. Superficially porous or core-shell particles achieve much of the same benefit at moderate pressure by shortening the diffusion path.
Pore diameter governs access. The classical hundred-ångström pore was developed for small molecules and becomes restrictive as analyte size rises; for larger peptides a phase with pores in the region of three hundred ångströms allows the molecule to enter the particle and interact with the full bonded surface rather than only the exterior. Using a narrow-pore column for a large peptide produces broad, poorly shaped peaks that are frequently attributed to the sample.
Bonded phase chemistry governs selectivity. Octadecyl silica is the default and covers most peptide work; octyl phases retain less and can help with very hydrophobic sequences; phenyl and polar-embedded phases offer genuinely different selectivity and are therefore candidates for an orthogonal second method. Column dimensions matter too: at constant particle size a longer column gives more resolution and more pressure, and halving the internal diameter quarters the solvent consumption.2
Integration is where the largest single share of the disagreement lives, and it is a software setting. Raise the threshold and small peaks leave the denominator; widen the solvent-front exclusion and early-eluting material leaves it too. Neither operation touches the sample.
Retention-time agreement is consistency. Molecular mass is composition. Only fragmentation approaches sequence.
On three claims that share one phraseA gradient should be quoted as a rate, not as a duration. Twenty-five to forty-five per cent acetonitrile over forty minutes is half a percentage point of organic per minute. The same range in twelve minutes is about one and two-thirds points per minute. That threefold difference in slope is the difference between resolving a deamidated relative from its parent and delivering both as one peak.
The underlying relationship is well established in peptide chromatography: resolution of closely related species improves as gradient slope decreases, up to the point where peak broadening from extended run times starts to give the gain back. Peak capacity — the number of peaks a method can theoretically resolve across its run — rises with shallower gradients and with more efficient columns, and it is the honest single-number summary of what a separation can do. It is never quoted in this trade.
The Journal’s standing request is simply that the gradient be printed. It is three numbers: starting composition, ending composition, time. Nobody regards it as commercially sensitive, every laboratory has it in the method file, and its presence converts a purity figure from an assertion into something comparable with the next certificate. Its absence is the reason two figures from two suppliers cannot be placed side by side, and that absence is a documentary decision rather than a technical constraint.3
| Disclosed item | On standard certificate | On request | Not available |
|---|---|---|---|
| Purity figure | 20 | 0 | 0 |
| Method named as HPLC | 20 | 0 | 0 |
| Detection wavelength | 5 | 6 | 9 |
| Gradient programme or rate | 1 | 5 | 14 |
| Integration threshold | 2 | 3 | 15 |
| Solvent-front exclusion window | 0 | 2 | 18 |
| Three largest impurities listed | 1 | 1 | 18 |
| Chromatogram attached | 4 | 7 | 9 |
| Compiled from standard release documentation and from a written questionnaire sent twice, four weeks apart. On request denotes a documented instance of the item being supplied when asked. Where a supplier attaches an independent laboratory report rather than transcribing a figure, the disclosure is credited to the certificate. | |||
Peptide separations are usually run with the column thermostatted somewhere between thirty and sixty degrees, and the temperature is doing more than stabilising retention times. Raising it lowers mobile-phase viscosity, which reduces backpressure and permits higher flow or smaller particles. It speeds mass transfer, narrowing peaks. And it changes selectivity, because the enthalpy of partitioning differs between species: two peaks that co-elute at thirty degrees may separate at fifty, and occasionally the reverse.
That last effect makes temperature a legitimate orthogonality lever, though a weaker one than changing pH or phase chemistry. It also makes it a source of irreproducibility when uncontrolled. A separation developed at ambient temperature in a cool laboratory and repeated in a warm one is not the same separation, and the retention-time drift that follows is frequently blamed on the column.
For peptides there is an additional consideration. Elevated temperature accelerates on-column degradation of labile sequences, and a peptide with an aspartate-proline bond held at sixty degrees in an acidic mobile phase for forty minutes may generate a fragment during the analysis. A purity figure obtained under such conditions includes a contribution the sample did not have when it was injected. This is not common and it is not hypothetical, and it is one reason method development for a labile peptide is not a matter of adopting a generic gradient.
A brief note on what this department does not allege. Nothing above suggests that any company is falsifying a measurement. The point throughout is that a defensible analytical choice, made honestly and documented nowhere, moves the answer by more than the differences buyers are being asked to price.
Particle size determines efficiency but not selectivity. A column packed with 1.7-micron particles will produce sharper peaks and narrower bandwidths than a 5-micron equivalent, which means better resolution of closely spaced peaks, but both columns separate according to hydrophobicity and both will fail to resolve species that do not differ sufficiently in that property. Resolution—the separation of two peaks, measured by their distance relative to their width—is the joint product of efficiency and selectivity, and improvement in one does not compensate for inadequacy in the other.2
A peptide method development sequence therefore cannot stop at efficiency. Running a smaller particle after a failed separation is a rational experiment, but it is not the only experiment, and it is frequently not the right one. A shallower gradient, a different pH, a temperature shift or a stationary-phase change addresses selectivity directly, and a successful method development programme tests each before concluding that only a smaller particle will serve. The practical consequence is that method robustness and lifetime depend on whether the selectivity separation is known and defended, or whether the method relies on brute-force efficiency to hide a hidden selectivity problem.
Ruggedness testing in regulated pharmaceutical practice submits a method to deliberate small changes in conditions—temperature within a range, flow rate within a percentage, mobile-phase pH within a fraction, column lot change—and confirms that the method gives acceptably similar answers under all those conditions. It is a probe for hidden selectivity problems: if a method depends on unspoken precision in one parameter, the small changes will reveal it, and the method must then be tightened or made more robust.4 A method that survives ruggedness testing is one that works because of its design choices, not because of luck.
Ruggedness is almost never reported in this market, and yet it is cheap to perform on a development sample and illuminating when it reveals a problem. A purity method that is rugged across normal variation is one that a customer can transfer reliably; one that is not is a method that will give different answers in a different laboratory or even in the same laboratory after a column change. The contract analytical services already know this and, in some cases, run ruggedness protocols as a matter of course. Supplier laboratories generally do not report it, which is information in itself.
The technique is not on trial here and never was. Reversed-phase chromatography can resolve species differing by a single methyl group, and the laboratories running it for this market are, on the evidence we have gathered, largely competent and entirely willing to describe what they did when somebody asks. What is on trial is a document format that omits the four values needed to compare one figure with another.
Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.
A short defence of long run times. Most of the disputes described in this series would be settled by adding fifteen minutes to the gradient and letting the late-eluting material come off inside the run rather than in the next injection. Throughput is the real reason methods are short, and throughput is a commercial value, not an analytical one.
— T. Nkemelu, Port Harcourt
On column temperature: the article treats it as one variable among twelve, but for peptides it is closer to a second gradient. Raising the compartment from thirty to sixty degrees sharpens peaks and can reverse an elution order. A certificate that states a temperature is telling you more than a certificate that states a column.
— C. Bąkowski, Łódź
Sub-two-micron columns changed everything about what is practical for peptide separations, but I would push back on the statement that particle size gains are costless. The pressure limit of most commercial instruments is three hundred bar, and trying to force 1.7-micron particles at eight millilitres per minute on a 4.6-millimetre column will send you there quickly. Peak capacity is not free.
— M. Tsvangirai, Bulawayo
Correct on the pressure cost, and that belongs in the method section. The trade-off is real, which is why many laboratories use core-shell superficially porous particles as a compromise: they are substantially cheaper than sub-two-micron packings, deliver most of the efficiency gain at a lower pressure, and the efficiency-cost-pressure triangle is the actual business decision people make. We should have named it.
On the denominator: I have seen certificates where the counter-ion peak was excluded and certificates where it was not, and the difference on a trifluoroacetate salt is not small. Neither certificate said which had been done. A single line stating what was excluded from the total area would settle it.
— A. Kozlova, Tbilisi
Reported from the analysis, not from a warning notice.
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
Reported from the analysis, not from a warning notice.
We submitted vials for endotoxin determination and report the results, the method and the laboratory, because a pyrogen figure without a method is as empty as a purity…
The supplier confirmed the determination and supplied the method behind its own figure inside a week.
A reminder that a purity figure is the output of a method, and that methods differ.